TY  - JOUR
AU  - Hoelscher, M.
AU  - Barros-Aguirre, D.*
AU  - Dara, M.*
AU  - Heinrich, N.*
AU  - Sun, E.*
AU  - Lange, C.*
AU  - Tiberi, S.*
AU  - Wells, C.M.*
C1  - 75748
C2  - 58141
TI  - Corrigendum to Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
JO  - Clin. Microbiol. Infect.
PY  - 2025
SN  - 1198-743X
ER  - 

TY  - JOUR
AB  - BACKGROUND: Tuberculosis (TB) is the leading cause of mortality by an infectious disease world-wide. Despite national and international efforts, the world is not on track to end TB by 2030. Antibiotic treatment of TB is longer than for most infectious diseases and complicated by frequent adverse events. To counter emerging Mycobacterium tuberculosis drug resistance and provide effective, safe drug treatments of shorter duration, novel anti-TB medicines and treatment regimens are needed. Through a joint global effort, more candidate medicines are in the clinical phases of drug development than ever before. OBJECTIVES: To review anti-TB medicines and treatment regimens under clinical evaluation for the future treatment of drug-susceptible and drug-resistant TB. SOURCES: Pre-clinical and clinical studies on novel anti-TB drugs. CONTENT: Description of novel protein synthesis inhibitors (oxazolidinones and oxaboroles), respiratory chain inhibitors (diarylquinolines and cytochrome bc1 complex inhibitor), cell wall inhibitors (DprE1 inhibitors, thioamides and carbapenems) and cholesterol metabolism inhibitor currently evaluated in clinical trials and novel clinical trial platforms for the evaluation of treatment regimens, rather than single entities. IMPLICATIONS: A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.
AU  - Hoelscher, M.
AU  - Barros-Aguirre, D.*
AU  - Dara, M.*
AU  - Heinrich, N.*
AU  - Sun, E.*
AU  - Lange, C.*
AU  - Tiberi, S.*
AU  - Wells, C.M.*
C1  - 70905
C2  - 55805
CY  - 125 London Wall, London, England
SP  - 1131-1138
TI  - Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
JO  - Clin. Microbiol. Infect.
VL  - 30
IS  - 9
PB  - Elsevier Sci Ltd
PY  - 2024
SN  - 1198-743X
ER  - 

TY  - JOUR
AB  - SCOPE: Since the onset of COVID-19, several assays have been deployed for the diagnosis of SARS-CoV-2. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first set of guidelines on SARS-CoV-2 in vitro diagnosis in February 2022. Because the COVID-19 landscape is rapidly evolving, the relevant ESCMID guidelines panel releases an update of the previously published recommendations on diagnostic testing for SARS-CoV-2. This update aims to delineate the best diagnostic approach for SARS-CoV-2 in different populations based on current evidence. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. The panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the population, intervention, comparison, and outcome (PICO) format was developed at the beginning of the process. For each PICO, 2 panel members performed a literature search focusing on systematic reviews with a third panellist involved in case of inconsistent results. The panel reassessed the PICOs previously defined as priority in the first set of guidelines and decided to address 49 PICO questions, because 6 of them were discarded as outdated/non-clinically relevant. The 'Grading of Recommendations Assessment, Development and Evaluation (GRADE)-adoption, adaptation, and de novo development of recommendations (ADOLOPMENT)' evidence-to-decision framework was used to produce the guidelines. QUESTIONS ADDRESSED BY THE GUIDELINES AND RECOMMENDATIONS: After literature search, we updated 16 PICO questions; these PICOs address the use of antigen-based assays among symptomatic and asymptomatic patients with different ages, COVID-19 severity status or risk for severe COVID-19, time since the onset of symptoms/contact with an infectious case, and finally, types of biomaterials used.
AU  - Fragkou, P.C.*
AU  - De Angelis, G.*
AU  - Menchinelli, G.*
AU  - Can, F.*
AU  - Garcia, F.*
AU  - Morfin-Sherpa, F.*
AU  - Dimopoulou, D.*
AU  - Dimopoulou, K.*
AU  - Zelli, S.*
AU  - de Salazar, A.*
AU  - Reiter, R.*
AU  - Janocha, H.*
AU  - Grossi, A.*
AU  - Omony, J.
AU  - Skevaki, C.*
C1  - 67676
C2  - 53983
CY  - The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
SP  - 876-886
TI  - Update of European Society of Clinical Microbiology and Infectious Diseases coronavirus disease 2019 guidelines: Diagnostic testing for severe acute respiratory syndrome coronavirus 2.
JO  - Clin. Microbiol. Infect.
VL  - 29
IS  - 7
PB  - Elsevier Sci Ltd
PY  - 2023
SN  - 1198-743X
ER  - 

TY  - JOUR
AB  - OBJECTIVES: The study aim was to assess predictors of negative antibody response (AbR) in solid organ transplant (SOT) recipients after the first booster of SARS-CoV-2 vaccination. METHODS: Solid organ transplant recipients receiving SARS-CoV-2 vaccination were prospectively enrolled (March 2021-January 2022) at six hospitals in Italy and Spain. AbR was assessed at first dose (t0), second dose (t1), 3 ± 1 month (t2), and 1 month after third dose (t3). Negative AbR at t3 was defined as an anti-receptor binding domain titre <45 BAU/mL. Machine learning models were developed to predict the individual risk of negative (vs. positive) AbR using age, type of transplant, time between transplant and vaccination, immunosuppressive drugs, type of vaccine, and graft function as covariates, subsequently assessed using a validation cohort. RESULTS: Overall, 1615 SOT recipients (1072 [66.3%] males; mean age±standard deviation [SD], 57.85 ± 13.77) were enrolled, and 1211 received three vaccination doses. Negative AbR rate decreased from 93.66% (886/946) to 21.90% (202/923) from t0 to t3. Univariate analysis showed that older patients (mean age, 60.21 ± 11.51 vs. 58.11 ± 13.08), anti-metabolites (57.9% vs. 35.1%), steroids (52.9% vs. 38.5%), recent transplantation (<3 years) (17.8% vs. 2.3%), and kidney, heart, or lung compared with liver transplantation (25%, 31.8%, 30.4% vs. 5.5%) had a higher likelihood of negative AbR. Machine learning (ML) algorithms showing best prediction performance were logistic regression (precision-recall curve-PRAUC mean 0.37 [95%CI 0.36-0.39]) and k-Nearest Neighbours (PRAUC 0.36 [0.35-0.37]). DISCUSSION: Almost a quarter of SOT recipients showed negative AbR after first booster dosage. Unfortunately, clinical information cannot efficiently predict negative AbR even with ML algorithms.
AU  - Giannella, M.*
AU  - Huth, M.
AU  - Righi, E.*
AU  - Hasenauer, J.
AU  - Marconi, L.*
AU  - Konnova, A.*
AU  - Gupta, A.*
AU  - Hotterbeekx, A.*
AU  - Berkell, M.*
AU  - Palacios-Baena, Z.R.*
AU  - Morelli, M.C.*
AU  - Tamè, M.*
AU  - Busutti, M.*
AU  - Potena, L.*
AU  - Salvaterra, E.*
AU  - Feltrin, G.*
AU  - Gerosa, G.*
AU  - Furian, L.*
AU  - Burra, P.*
AU  - Piano, S.*
AU  - Cillo, U.*
AU  - Cananzi, M.*
AU  - Loy, M.*
AU  - Zaza, G.*
AU  - Onorati, F.*
AU  - Carraro, A.*
AU  - Gastaldon, F.*
AU  - Nordio, M.*
AU  - Kumar-Singh, S.*
AU  - Baño, J.R.*
AU  - Lazzarotto, T.*
AU  - Viale, P.*
AU  - Tacconelli, E.*
C1  - 67767
C2  - 54245
CY  - The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
SP  - 1084.e1-1084.e7
TI  - Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: The multicentre ORCHESTRA cohort.
JO  - Clin. Microbiol. Infect.
VL  - 29
IS  - 8
PB  - Elsevier Sci Ltd
PY  - 2023
SN  - 1198-743X
ER  - 

TY  - JOUR
AB  - Human bocavirus (HBoV) was recently described as a new member of the Parvoviridae. In order to investigate the suggested association of HBoV with respiratory and gastric disease in infants and young children, sera of 357 paediatric patients hospitalized with infectious and non-infectious diseases were retrospectively analyzed for the presence of HBoV DNA and virus-specific antibodies using quantitative PCR and ELISA, respectively. HBoV seroprevalence was determined to range from 25% in infants younger than 1 year of age to 93% in children aged more than 3 years. Viral loads between 1 x 10(2) and 1.2 x 10(6) geq/mL were observed in 6.7% (20/297) of sera obtained preferentially from young children suffering from infectious diseases. HBoV genomes were furthermore detected in 5% (3/60) of sera collected from individuals with non-infectious illnesses. HBoV DNA was present most frequently in patients with respiratory disease (9.6%). Whereas only 5.2% of patients with upper respiratory tract disease were viraemic, HBoV DNA was found in 14.6% and 10.0% of patients with lower respiratory tract illness and pneumonia, respectively. Acute HBoV infections were also observed in 7.5% of patients with gastroenteritis and in one child with inflammatory bowel disease. None of 77 patients hospitalized for various other infectious diseases (e.g. rash, urinary tract infection, meningitis) displayed viraemia. In 60.9% and 47.8% of DNA-positive children, HBoV-specific IgM and IgG was observed, respectively. The present prospective study provides comprehensive data on the clinical association of acute HBoV infection with respiratory illness and on the seroprevalence of virus-specific antibodies in children.
AU  - Karalar, L.*
AU  - Lindner, J.
AU  - Schimanski, S.*
AU  - Kertai, M.*
AU  - Segerer, H.*
AU  - Modrow, S.*
C1  - 2944
C2  - 28100
CY  - Malden
SP  - 633-639
TI  - Prevalence and clinical aspects of human bocavirus infection in children.
JO  - Clin. Microbiol. Infect.
VL  - 16
IS  - 6
PB  - Wiley-Blackwell Publishing Inc.
PY  - 2010
SN  - 1198-743X
ER  -